Singapore, Oct. 13 -- GC Biopharma, a South Korean biopharmaceutical company, has signed an agreement with Curevo Vaccine to secure contract manufacturing (CMO) rights for amezosvatein (CRV-101), a recombinant shingles vaccine currently under clinical development.

Under the terms of the agreement, GC Biopharma will be responsible for producing a portion of the commercial supply of amezosvatein for global markets.

The global shingles vaccine market is currently dominated by GSK's Shingrix. Since its launch in 2018, the market has grown at an average annual rate of approximately 20%, expanding fromKRW 1 trillionin 2017 to aroundKRW 6 trillion(~$4.4 billion) in 2024. Shingrix recorded overKRW 5 trillion(GBP 3.4 billion) in global sales las...